Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone.
The purpose of this experiment is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone.
There will be a total of 50 subjects:
Study Timelines:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Almond oil | Experimental | Almond Oil Pressed Cold |
|
| Hydroquinone | Active Comparator | Hydroquinone 2% cream |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Almond Oil | Other | Almond oil |
| |
| Hydroquinone Topical |
| Measure | Description | Time Frame |
|---|---|---|
| Intensity of facial pigment | Facial images will be obtained and analyzed with the BTBP image analysis system | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Shifts in the microbiome diversity (Shannon index as an example) | The skin microbiome will be analyzed to assess any changes after topical almond oil application, compared to the use of topical hydroquinone. | 16 weeks |
| Quantification for the presence of species within the genus Cutibacteria, Staphyloccoccus, and Ralstonia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Those with a nut allergy
Smoking is an independent risk factor and serves as a confounder for the development of facial aging [18]. Therefore current smokers, those that have smoked within the past year, and former smokers with greater than a 20 pack year history of smoking will be excluded.
Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndrome) will be excluded as this can be a confounder for facial photoaging.
Hormonal medications or therapies will not be allowed unless they have been stable on their medications for at least 2 months. Examples include oral contraceptives, progesterone-based injections, and estrogen based hormonal replacement therapy.
Those who have undergone any cosmetic procedures to the face in the 4 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment will also not be eligible.
Individuals who are unwilling to discontinue vitamin E containing supplements and food sources during the washout and intervention.
Individual who are unwilling to discontinue topical cosmetic products during the duration of the study.
Individuals who are not willing to engage in a two-week washout on topical treatments known to affect facial pigmentation and these agents will be restricted during the study period as well. These include topicals that contain:
Furthermore, subjects will be asked to refrain from use of any other topical products for one week prior to each visit apart from the study agents supplied from this study.
Premenopausal women
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Iryna Rybak | Contact | 916-551-2636 | irybak@ucdavis.edu | |
| Alexis Carrington | Contact | aecarrington@ucdavis.edu |
| Name | Affiliation | Role |
|---|---|---|
| Raja Sivamani, MD MS AP | UC Davis Dermatology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC Davis Department of Dermatology, Clinical Trials Unit | Recruiting | Sacramento | California | 95816 | United States |
Not provided
| Label | URL |
|---|---|
| Learn more or sign up for the study here! | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010859 | Pigmentation Disorders |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C068582 | almond oil |
| C031927 | hydroquinone |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Hydroquinone 2% cream |
|
|
The skin microbiome will be analyzed to assess the presence of species within the genus Cutibacteria, Staphyloccoccus, and Ralstonia |
| 16 weeks |
| Appearance of facial redness | The research team will quantify the presence of facial redness with a SkinColorCatch from Delfin Technologies. This will measure the RGB colors and average them from each participant for each of the visits. Skin pigment, including the presence of redness, will be measured using a SkinColorCatch from Delfin Technologies. This device shows the RGB Colors, CIE L*a*b* and L*c*h* color space coordinates when the device is applied to the skin.Included is the link to the device (http://www.truesystem.co.kr/product/pdf/SkinColorCatch%20Brochure%202016.pdf). | 16 weeks |
| Subjective tolerability assessment | A questionnaire that assesses for stinging, itching, and burning will be utilized. | 16 weeks |
| Intensity of facial pigment | Facial images will be obtained and analyzed with the BTBP image analysis system | 8 weeks |